See more : Aura Smart Air Ltd (AUSA.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Therma Bright Inc. (TBRIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Therma Bright Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Public Joint Stock Company Rosseti South (MRKY.ME) Income Statement Analysis – Financial Results
- Telkom SA SOC Limited (TLKGY) Income Statement Analysis – Financial Results
- Nabati Foods Global Inc. (MEAL.CN) Income Statement Analysis – Financial Results
- BactiQuant A/S (BACTIQ.CO) Income Statement Analysis – Financial Results
- Frontken Corporation Berhad (0128.KL) Income Statement Analysis – Financial Results
Therma Bright Inc. (TBRIF)
About Therma Bright Inc.
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.07K | 23.90K | 139.43K | 3.88K | 3.78K | 6.91K | 14.10K | 31.16K | 4.79K | 1.71K | 0.00 | 0.00 | 0.00 | 0.00 | 172.75K | 251.02K | 250.86K | 770.03K | 43.81K | 38.54K | 37.83K | 6.50K |
| Cost of Revenue | 614.00 | 0.00 | 75.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 439.00 | 0.00 | 0.00 | 0.00 | 0.00 | 141.00K | 372.71K | 121.96K | 281.02K | 27.43K | 24.08K | 23.72K | 0.00 |
| Gross Profit | 25.46K | 23.90K | 63.48K | 3.88K | 3.78K | 6.91K | 14.10K | 31.16K | 4.79K | 1.27K | 0.00 | 0.00 | 0.00 | 0.00 | 31.75K | -121.69K | 128.90K | 489.01K | 16.38K | 14.45K | 14.11K | 6.50K |
| Gross Profit Ratio | 97.64% | 100.00% | 45.53% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 74.31% | 0.00% | 0.00% | 0.00% | 0.00% | 18.38% | -48.48% | 51.38% | 63.50% | 37.38% | 37.50% | 37.30% | 100.00% |
| Research & Development | 9.69K | 446.58K | 805.54K | 1.37M | 13.08K | 60.67K | 92.49K | 97.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 570.00 | 9.05K | 58.65K | 0.00 | 0.00 |
| General & Administrative | 1.15M | 3.18M | 4.94M | 7.17M | 597.83K | 346.27K | 1.16M | 898.70K | 210.34K | 351.86K | 440.91K | 317.77K | 0.00 | 0.00 | 756.94K | 0.00 | 0.00 | 0.00 | 0.00 | 704.05K | 706.22K | 26.73K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 68.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 343.04K | 0.00 | 0.00 | 0.00 | 0.00 | 2.12K | 23.22K | 115.00 |
| SG&A | 1.15M | 3.18M | 4.94M | 7.17M | 597.83K | 346.27K | 1.16M | 898.70K | 210.34K | 351.86K | 440.91K | 317.77K | 262.41K | 193.63K | 1.10M | 1.30M | 1.22M | 1.96M | 1.15M | 706.17K | 729.44K | 26.84K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.15M | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.16M | 3.63M | 5.90M | 8.60M | 613.89K | 409.73K | 1.25M | 996.51K | 210.34K | 351.86K | 440.91K | 317.77K | 262.41K | 193.63K | 1.11M | 1.32M | 1.31M | 2.10M | 1.18M | 713.41K | 931.71K | 28.10K |
| Cost & Expenses | 1.16M | 3.63M | 5.98M | 8.60M | 613.89K | 409.73K | 1.25M | 996.51K | 210.34K | 352.30K | 440.91K | 317.77K | 262.41K | 193.63K | 1.25M | 1.70M | 1.43M | 2.38M | 1.21M | 737.49K | 955.43K | 28.10K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.06K | 0.00 | 0.00 |
| Interest Expense | 8.60K | 13.44K | 1.38K | 0.00 | 17.40K | 18.91K | 8.74K | 0.00 | 0.00 | 3.90K | 643.97K | 550.99K | 473.02K | 423.68K | 312.72K | 267.74K | 0.00 | 0.00 | 0.00 | 1.27K | 0.00 | 0.00 |
| Depreciation & Amortization | 99.51K | 75.38K | 53.85K | 57.98K | 2.98K | 2.79K | 76.00 | 247.00 | 22.82K | 3.90K | 1.80M | 2.30M | 473.02K | 423.68K | 8.89K | 20.34K | 97.21K | 136.62K | 35.73K | 21.00K | 202.27K | 163.63K |
| EBITDA | -2.34M | -3.68M | -5.73M | -8.55M | -606.31K | -400.24K | -1.24M | -965.10K | -205.55K | -350.59K | 710.24K | 1.43M | -262.41K | -193.63K | -1.07M | -1.82M | -1.09M | -1.47M | -1.13M | -1.35M | -466.92K | -715.33K |
| EBITDA Ratio | -8,988.07% | -15,393.76% | -4,077.18% | -219,824.44% | -16,048.82% | -5,793.37% | -8,768.46% | -3,096.93% | -4,288.52% | -20,514.16% | 0.00% | 0.00% | 0.00% | 0.00% | -618.36% | -567.40% | -433.19% | -190.85% | -2,582.01% | -1,759.32% | -1,890.80% | 2,184.40% |
| Operating Income | -1.14M | -3.60M | -5.68M | -8.54M | -607.13K | -400.03K | -1.24M | -965.34K | -205.55K | -354.49K | -1.08M | -868.76K | -735.43K | -617.31K | -1.09M | -1.44M | -1.18M | -1.61M | -1.17M | -698.95K | -917.60K | -21.60K |
| Operating Income Ratio | -4,355.04% | -15,076.51% | -4,077.18% | -219,824.44% | -16,048.82% | -5,793.37% | -8,769.00% | -3,097.72% | -4,288.52% | -20,742.36% | 0.00% | 0.00% | 0.00% | 0.00% | -633.18% | -575.50% | -471.94% | -208.59% | -2,663.56% | -1,813.82% | -2,425.45% | -332.17% |
| Total Other Income/Expenses | -1.32M | -164.64K | -196.39K | -74.54K | -19.56K | -21.90K | -8.81K | -247.00 | -472.00 | -1.88K | 1.15M | 1.73M | -41.06K | 0.00 | -420.04K | -390.97K | -228.63K | -95.70K | 17.40K | -589.48K | 3.76K | -42.30K |
| Income Before Tax | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K | -421.93K | -1.24M | -965.59K | -206.02K | -356.37K | 68.21K | 860.04K | -735.43K | -617.31K | -1.51M | -1.84M | -1.41M | -1.70M | -1.15M | -1.96M | -959.90K | -21.65K |
| Income Before Tax Ratio | -9,402.79% | -15,765.40% | -4,218.03% | -221,744.06% | -16,565.74% | -6,110.51% | -8,769.54% | -3,098.51% | -4,298.37% | -20,852.60% | 0.00% | 0.00% | 0.00% | 0.00% | -876.33% | -731.25% | -563.07% | -221.02% | -2,623.86% | -5,079.90% | -2,537.27% | -332.93% |
| Income Tax Expense | 0.00 | 0.00 | 1.38K | -178.58K | 17.40K | 18.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 312.72K | 267.74K | 195.65K | 133.18K | 20.67K | 361.30K | -295.99K | -9.50K |
| Net Income | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K | -421.93K | -1.24M | -965.59K | -206.02K | -356.37K | 68.21K | 860.04K | -735.43K | -617.31K | -1.51M | -2.10M | -1.61M | -1.84M | -1.15M | -2.32M | -663.91K | -12.15K |
| Net Income Ratio | -9,402.79% | -15,765.40% | -4,218.03% | -221,744.06% | -16,565.74% | -6,110.51% | -8,769.54% | -3,098.51% | -4,298.37% | -20,852.60% | 0.00% | 0.00% | 0.00% | 0.00% | -876.33% | -837.92% | -641.07% | -238.31% | -2,623.86% | -6,017.49% | -1,754.88% | -186.82% |
| EPS | -0.01 | -0.02 | -0.03 | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.06 | -0.02 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.06 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 315.92M | 242.84M | 228.45M | 199.96M | 163.80M | 163.27M | 148.52M | 116.63M | 110.35M | 88.46M | 78.09M | 69.12M | 66.78M | 66.78M | 55.93M | 52.28M | 49.17M | 44.68M | 40.80M | 39.76M | 32.58M | 20.05M |
| Weighted Avg Shares Out (Dil) | 315.92M | 242.84M | 228.45M | 199.96M | 163.80M | 163.27M | 148.52M | 116.63M | 110.35M | 88.46M | 78.09M | 69.12M | 66.78M | 66.78M | 55.93M | 52.28M | 49.17M | 44.68M | 40.80M | 39.76M | 32.58M | 20.05M |
Therma Bright Congratulates John Patton, PhD of InStatin on Receiving the Prestigious Charles G. Thiel Award
Chairman of Therma Bright's Strategic Investment Partner Recognized for Outstanding Research and Discovery in Respiratory Drug Delivery Toronto, Ontario--(Newsfile Corp. - September 4, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment...
Therma Bright Major Milestone: Portfolio Company Inretio's Preva(R) Device Achieves 3rd Human Trial Success
Game-Changing Innovation Poised to Transform Stroke and Blood Clot Treatment Therma Bright's Strategic Investment Helps Medical Device Company Demonstrate Efficacy and Safety in Transforming Ischemic Stroke Care Toronto, Ontario--(Newsfile Corp. - August 27, 2024) - Therma Bright Inc. (TSXV: THRM)...
RETRANSMISSION: Therma Bright Secures Nationwide U.S. Distribution Partner For Venowave
Nationwide partner launches initial Venowave sales program to gauge Medicare/Medicaid reimbursement timelines and billing procedures Post initial program success, distributor commits to acquire remaining inventory that totals up to USD $2.38M in reimbursement value Toronto, Ontario--(Newsfile Corp. - August 23,...
Therma Bright Secures Nationwide U.S. Distribution Partner For Venowave
Nationwide partner launches initial Venowave sales program to gauge Medicare/Medicaid reimbursement timelines and billing procedures Post initial program success, distributor commits to acquire remaining inventory that totals up to USD $2.38M in reimbursement value Toronto, Ontario--(Newsfile Corp. - August 22,...
Therma Bright's Venowave VW5 Secures Permanent HCPCS Code E0683 from U.S. DHHS's Centers for Medicare & Medicaid Services
The device becomes the first-of-its-kind Durable Medical Equipment to receive a new HCPCS Level II designation Company looks to provide a U.S. sales update in the coming week Toronto, Ontario--(Newsfile Corp. - August 19, 2024) - Therma Bright Inc. (TSXV:...
Therma Bright's AI-Powered Digital Cough Technology Being Considered as Partner Technology in New Chronic Cough Drug Clinical Trial
Toronto, Ontario--(Newsfile Corp. - August 16, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce...
Therma Bright Welcomes Medical & Pharmaceutical Veteran Michael Raimondo to Its Advisory Board
New Advisory Board Member Will Initially Focus On Venowave Sales & Business Development Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide...
Therma Bright Expands InStatin Investment
Toronto, Ontario--(Newsfile Corp. - August 6, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide...
Therma Bright Receives Positive Notification from U.S. DHHS's Centers for Medicare & Medicaid (CMS)
Company anticipates CMS permanent CPT(R) and HCPCS codes in the coming days Toronto, Ontario--(Newsfile Corp. - August 1, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range...
Therma Bright's Venowave VW5 Secures FDA 510K Approval
Toronto, Ontario--(Newsfile Corp. - July 29, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce...
Source: https://incomestatements.info
Category: Stock Reports